HOWL
Werewolf Therapeutics, Inc.
Key Financials
Operating Income
$-60677000
↑ 17.6%
Net Income
$-60822000
↑ 13.7%
Total Liabilities
$44.6M
↓ 16.7%
Total Assets
$69.4M
↓ 45.3%
Cash & Equivalents
$57.0M
↓ 48.6%
Shareholders' Equity
$24.8M
↓ 66.2%
Long-term Debt
$32.1M
0.0%
EPS (Diluted)
$-1.33
↑ 18.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 7/2/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| SCHEDULE 13D/A | 6/26/2026 | View on SEC |
| SCHEDULE 13D/A | 6/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HOWL |
| Company Name | Werewolf Therapeutics, Inc. |
| CIK | 1785530 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-952-0555 |